Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of BIO89-100 in Subjects With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

27 Feb 2025 According to a 89bio media release, data analyses from the Phase 2b ENLIVEN trial highlighting the potential anti-fibrotic effects and the potential utility of non-invasive tests correlating with histological endpoints were presented at the 75th Annual American Association for the Study of Liver Diseases (AASLD) The Liver Meeting in November 2024.
07 Feb 2025 Status changed from active, no longer recruiting to completed.
15 Nov 2024 According to a 89bio media release, company will present additional analyses from our Phase 2b ENLIVEN trial at this year's Liver Meeting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com